A new Delphi consensus led by the National Psoriasis Foundation proposes a standardized definition of on-treatment remission ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

Tumor necrosis factor (TNF) inhibitor therapy was effective in reducing the likelihood that psoriasis would progress to ...

Scores range from 0 to 72. A score of more than 10 generally translates to “moderate-to-severe.” A score of more than 40 is rare. Usually, the higher your PASI score, the lower your quality of ...

Half of the patients had 90% skin clearance by the Psoriasis Area and Severity Index (PASI 90) ... P<0.001) and a Psoriasis Symptom and Sign Diary score of 0 (20% vs 1%).

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

In the analysis, 77% and 75% of patients had an absolute PASI score of 3 or lower at 6 and 12 months, respectively. An absolute PASI of 1 or lower was achieved by 65% and 64% of patients at 6 and ...

Chinese biopharmaceutical company Innovent Biologics has reported that its Phase III CLEAR-1 study of picankibart (IBI112) for treating moderate to severe plaque psoriasis met all its primary and ...

The percentage decrease in PASI score was 65.3% in the apremilast group and 38.3% in the placebo group, which the authors called a significant difference (P < .0001).

Also, secondary endpoints included a 75% reduction in PASI score (PASI 75) and an IGA score of 0 or 1 (clear or almost clear), along with a 2-point or more improvement in IGA. Of the 202 patients ...

Evelo Biosciences Inc. EVLO said Tuesday it’s reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal.

The study's primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score (a PASI-50 ...